Vani Santosh

Dr. Vani Santosh

National Institute of Mental Health and Neuro Sciences, Bengaluru, India

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2019 in Brain Tumor Pathology
Verified
Journal Article
Closed access
RMRadhika Mhatre
Radhika Mhatre
HSHarsha S. Sugur
Harsha S. Sugur
BNB. N. Nandeesh
B. N. Nandeesh
YCYasha Chickabasaviah
Yasha Chickabasaviah
JSJ. Saini
J. Saini
Vani SantoshVani Santosh
Vani Santosh

6 December 2010 in Neuropathology
Verified
Journal Article
Closed access
PDF file
MSMallavarapu R. Srividya
Mallavarapu R. Srividya
BTBalaram Thota
Balaram Thota
BSBangalore C. Shailaja
Bangalore C. Shailaja
AAArimappamagan Arivazhagan
Arimappamagan Arivazhagan
KTKandavel Thennarasu
Kandavel Thennarasu
Vani SantoshVani Santosh
Vani Santosh

21 November 2016 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
ZNZahid Nawaz
Zahid Nawaz
VPVikas Patil
Vikas Patil
YPYashna Paul
Yashna Paul
AHAlangar S. Hegde
Alangar S. Hegde
AAArimappamagan Arivazhagan
Arimappamagan Arivazhagan
KSKumaravel Somasundaram
Kumaravel Somasundaram
Glioblastomas (GBM) continue to remain one of the most dreaded tumours that are highly infiltrative in nature and easily preclude comprehensive surgical resection. GBMs pose an intricate etiology as they are being associated with a plethora of genetic and epigenetic lesions. Misregulation of the PI3 kinase pathway is one of the most familiar events in GBM. While the PI3 kinase signalling regulated pathways and genes have been comprehensively studied, its impact on the miRNome is yet to be explored. The objective of this study was to elucidate the PI3 kinase pathway regulated miRNAs in GBM. miRNA expression profiling was conducted to monitor the differentially regulated miRNAs upon PI3 kinase pathway abrogation. qRT-PCR was used to measure the abundance of miR-326 and its host gene encoded transcript. Proliferation assay, colony suppression assay and wound healing assay were carried out in pre-miR transfected cells to investigate its role in malignant transformation. Potential targets of miR-326 were identified by transcriptome analysis of miR-326 overexpressing cells by whole RNA sequencing and selected targets were validated. Several publically available data sets were used for various investigations described above. We identified several miRNA that were regulated by PI3 kinase pathway. miR-326, a GBM downregulated miRNA, was validated as one of the miRNAs whose expression was alleviated upon abrogation of the PI3 kinase pathway. Overexpression of miR-326 resulted in reduced proliferation, colony suppression and hindered the migration capacity of glioma cells. Arrestin, Beta 1 (ARRB1), the host gene of miR-326, was also downregulated in GBM and interestingly, the expression of ARRB1 was also alleviated upon inhibition of the PI3 kinase pathway, indicating similar regulation pattern. More importantly, miR-326 exhibited a significant positive correlation with ARRB1 in terms of its expression. Transcriptome analysis upon miR-326 overexpression coupled with integrative bioinformatics approach identified several putative targets of miR-326. Selected targets were validated and interestingly found to be upregulated in GBM. Taken together, our study uncovered the PI3 kinase regulated miRNome in GBM. miR-326, a PI3 kinase pathway inhibited miRNA, was demonstrated as a tumour suppressor miRNA in GBM.

1 January 2019 in Neurology India
Verified
Journal Article
Closed access
Vani SantoshVani Santosh
Vani Santosh
SPSravya Palavalasa
Sravya Palavalasa
TGTejpal Gupta
Tejpal Gupta
DMDattatraya Muzumdar
Dattatraya Muzumdar
GCGeeta Chacko
Geeta Chacko
RJRakesh Jalali
Rakesh Jalali
Lar tests to reach a definitive integrated diagnosis in most of the cases. This comes with additional cost and higher turnaround time, which is not always affordable in developing countries like India. In addition, the non-uniform distribution of advanced research and diagnostic testing centers adds to the difficulty. Methods: The Indian Society of Neuro-oncology (ISNO) multidisciplinary expert panel consisting of neuropathologists, neurosurgeons, and radiation/medical oncologists convened to prepare the national consensus guidelines for approach to diagnosis of adult diffuse gliomas. Results: Algorithms for arriving at an integrated diagnosis of adult diffuse gliomas predominantly using immunohistochemistry and with minimum possible additional molecular testing were agreed upon, thus addressing the problems of cost, accessibility, and turnaround time. Mandatory and optional tests were proposed for each case scenario. Conclusion: This document represents the consensus of the various neuro-oncology disciplines involved in diagnosis and management of patients with adult diffuse gliomas. The article reflects a practical adaptation of the WHO recommendations to suit a resource constrained setup....

1 August 2014 in Journal of Neurosurgery
Verified
Journal Article
Closed access
BTBalaram Thota
Balaram Thota
AAArivazhagan Arimappamagan
Arivazhagan Arimappamagan
TKThennarasu Kandavel
Thennarasu Kandavel
ASArun H. Shastry
Arun H. Shastry
PPParitosh Pandey
Paritosh Pandey
Vani SantoshVani Santosh
Vani Santosh
Object: Insulin-like growth factor binding proteins (IGFBPs) have been implicated in the pathogenesis of glioma. In a previous study the authors demonstrated that IGFBP-3 is a novel glioblastoma biomarker associated with poor survival. Since signal transducer and activator of transcription 1 (STAT-1) has been shown to be regulated by IGFBP-3 during chondrogenesis and is a prosurvival and radioresistant molecule in different tumors, the aim in the present study was to explore the functional significance of IGFBP-3 in malignant glioma cells, to determine if STAT-1 is indeed regulated by IGFBP-3, and to study the potential of STAT-1 as a biomarker in glioblastoma. Methods: The functional significance of IGFBP-3 was investigated using the short hairpin (sh)RNA gene knockdown approach on U251MG cells. STAT-1 regulation by IGFBP-3 was tested on U251MG and U87MG cells by shRNA gene knockdown and exogenous treatment with recombinant IGFBP-3 protein. Subsequently, the expression of STAT-1 was analyzed with real-time reverse transcription–polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) in glioblastoma and control brain tissues. Survival analyses were done on a uniformly treated prospective cohort of adults with newly diagnosed glioblastoma (136 patients) using Kaplan-Meier and Cox regression models. Results: IGFBP-3 knockdown significantly impaired proliferation, motility, migration, and invasive capacity of U251MG cells in vitro (p < 0.005). Exogenous overexpression of IGFBP-3 in U251MG and U87MG cells demonstrated STAT-1 regulation. The mean transcript levels (by real-time RT-PCR) and the mean labeling index of STAT-1 (by IHC) were significantly higher in glioblastoma than in control brain tissues (p = 0.0239 and p < 0.001, respectively). Multivariate survival analysis revealed that STAT-1 protein expression (HR 1.015, p = 0.033, 95% CI 1.001–1.029) along with patient age (HR 1.025, p = 0.005, 95% CI 1.008–1.042) were significant predictors of shorter survival in patients with glioblastoma. Conclusions: IGFBP-3 influences tumor cell proliferation, migration, and invasion and regulates STAT-1 expression in malignant glioma cells. STAT-1 is overexpressed in human glioblastoma tissues and emerges as a novel prognostic biomarker.

3 January 2021 in Journal of Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
VNVidya P. Nimbalkar
Vidya P. Nimbalkar
BKBanavathy S. Kruthika
Banavathy S. Kruthika
PSPalavalasa Sravya
Palavalasa Sravya
SRShilpa Rao
Shilpa Rao
HSHarsha S. Sugur
Harsha S. Sugur
Vani SantoshVani Santosh
Vani Santosh